Altimmune, a clinical-stage biopharmaceutical company in Gaithersburg, Maryland, develops peptide-based therapeutics for obesity and liver diseases, including the lead candidate pemvidutide. The company has completed Phase II trials for both pemvidutide and HepTcell, targeting metabolic dysfunction and hepatitis B.
ALT has been in the news recently: A class action lawsuit has been filed against Altimmune, Inc. for allegedly providing misleading information to investors during the securities purchase period from August 10, 2023, to June 25, 2025. This follows a significant drop in the company's stock price, which fell from $7.71 to $3.61 after disappointing trial results were announced.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
